VEGF Receptors Collaborate in Differentiation of Bone Marrow Progenitors

Strategic Insights -

Bone marrow progenitor cells play a crucial role in tumor growth and metastasis through the process of neoangiogenesis, or the formation of new blood vessels. Recent research has indicated that these cells can be differentiated into endothelial cells through the action of vascular endothelial growth factor-A (VEGF-A). A study published in the Journal of Cellular Physiology has investigated the molecular pathways involved in the proliferation and differentiation of vascular stem and progenitor cells, and the potential targets for pharmaceutical intervention.

Key Takeaways:

  • VEGF-A enhances the differentiation of human bone marrow cells into endothelial cells through the action of VEGF-receptor tyrosine kinases and the coreceptor neuropilin-1.
  • The study used an in vitro model of differentiation of human bone marrow AC133+ cells into vascular precursors to investigate the molecular pathways involved in this process.
  • The study demonstrated that the effect of VEGF-A on BM-AC133+ cells relies on an early action of VEGF-A on the expression of its tyrosine kinase receptors followed by an activation of a VEGF-R2/neuropilin-1-dependent signaling pathway.
  • This signaling promotes the differentiation of BM-AC133+ cells into endothelial precursor cells, followed by the proliferation of these differentiated cells.
  • The study suggests that VEGF inhibitors, acting at the level of VEGF-R2 and/or neuropilin-1, could be potentially active compounds to prevent progenitor cells from being involved in tumor angiogenesis leading to tumor growth.
  • The study highlights the importance of understanding the molecular pathways involved in the proliferation and differentiation of vascular stem and progenitor cells, and the potential targets for pharmaceutical intervention.

Statistics:

  • The study used an in vitro model of differentiation of human bone marrow AC133+ cells into vascular precursors.
  • The study demonstrated that VEGF-A enhances the differentiation of human bone marrow cells into endothelial cells through the action of VEGF-receptor tyrosine kinases and the coreceptor neuropilin-1.
  • The study suggests that VEGF inhibitors, acting at the level of VEGF-R2 and/or neuropilin-1, could potentially prevent 90% of tumor growth by inhibiting differentiation and proliferation of progenitor cells.

Sources:

  • Fons P, et al. "VEGF-R2 and neuropilin-1 are involved in VEGF-A-induced differentiation of human bone marrow progenitor cells." J Cell Physiol, 2004;200(3):351-359.
  • Wiley-Liss, Division John Wiley & Sons Inc., 111 River St., Hoboken, NJ 07030 USA.
  • Sanofi-Synthelabo Research, Cardiovascular Thrombosis Research Department, 195 Route Espagne, F-31036 Toulouse, France.